Nat. Med. 23, 439–449 (2017); published online 20 February 2017; corrected after print 26 July 2017
In the version of this article initially published, the authors inadvertently left out information in the Online Methods section regarding a second injection of AAV8-CFLAR(S1) 7 weeks after the first injection in the monkey experiments to ensure stable expression of CFLAR(S1) in the livers of the monkeys that received the injections. This correction does not change any results or conclusions of the paper. The error has been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nm.4290
Rights and permissions
About this article
Cite this article
Wang, PX., Ji, YX., Zhang, XJ. et al. Correction: Corrigendum: Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat Med 23, 1241 (2017). https://doi.org/10.1038/nm1017-1241b
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1017-1241b
This article is cited by
-
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Signal Transduction and Targeted Therapy (2022)
-
Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates
Nature Medicine (2018)
